An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Esomeprazole

Criteria

Inclusion Criteria:

• Critically ill male or female subjects 18 years or older who have a baseline gastric aspirate pH less then or equal to 4

• Subjects admitted to an ICU requiring mechanically ventilated

• Subjects will have at least one additional stress ulcer risk factor

Exclusion Criteria:

• Anticipated use of pre-pyloric enteral feeding after screening until the end of study

• Physician estimated survival of less then 96 hours

• Anticipation of major surgery within 96 hours of study enrollment